Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Kyoto
Clinical trial register · Japan

Clinical Trials in Kyoto, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AbbVie24 AstraZeneca21 Eli Lilly and Company17 Novartis Pharmaceuticals10 Hoffmann-La Roche9
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Kyoto

231 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Kurume-shi, Sapporo, Kumamoto, Kyoto, Matsumoto-shi, Suita-shi, Bunkyo-ku, Shinjuku-ku
2027-11-23
Not yet open
Bayer
Phase 2
8
Nagoya, Yokohama, Toyonaka, Bunkyo-ku, Kyoto
2027-01-25
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 1/2
50
Chiba, Kashiwa, Fukuoka, Hiroshima, Sapporo, Kanazawa, Yokohama, Kyoto
2026-09-15
Recruiting
A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors
NCT07801508Advanced Gastroesophageal Adenocarcinoma, Advanced Breast Cancer, Triple-negative Breast Cancer, Advanced Non-small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 1
66
Kyoto
2026-09-08
Not yet open
Breakthrough Platform Trial for PCAS
NCT07769086Cardiac Arrest (CA), Post Cardiac Arrest Syndrome
Kagawa University
Not applicable
630
Chiba, Iizuka, Hiroshima, Kobe, Kita-gun, Kyoto, Sendai, Okayama
2026-09-01
Not yet open
Kyoto University, Graduate School of Medicine
Observational
10,000
Kyoto
2026-09
Recruiting
AstraZeneca
Phase 3
500
Chūōku, Ichinomiya-shi, Izunokuni-shi, Kamakura-shi, Kawagoe-shi, Kitakyushu-shi, Kyoto, Mito
2026-08-24
Recruiting
A Study of LY3971297 in Participants With Heart Failure
NCT07547540Heart Failure, Heart Failure, Diastolic, Heart Failure, Systolic
Eli Lilly and Company
Phase 1
90
Kobe, Kyoto, Suita-shi, Tsuchiura-shi
2026-08-11
Recruiting
Regeneron Pharmaceuticals
Phase 3
15,364
Kyoto
2026-08-10
Recruiting
AstraZeneca
Phase 3
600
Asahikawa-shi, Kamakura-shi, Kashiwa-shi, Kobe, Komoro, Kumamoto, Kyoto, Miyazaki
2026-07-08
Recruiting
AstraZeneca
Phase 3
900
Chigasaki-shi, Chikushino-shi, Gifu, Kagoshima, Kitakyushu, Kumamoto, Kyoto, Maebashi
2026-07-06
Active, closed
GlaxoSmithKline
Phase 3
102
Aichi, Chiba, Fukui, Fukuoka, Fukushima, Hokkaido, Kanagawa, Kyoto
2026-06-29
Recruiting
AstraZeneca
Phase 3
750
Fukuoka, Kyoto, Nishinomiya-shi, Okayama, Sapporo, Shibuya-ku, Shinjuku-ku, Suita-shi
2026-06-26
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
20
Nagoya, Sapporo, Kobe, Chūō, Fukuoka, Kyoto
2026-06-23
Recruiting
Hoffmann-La Roche
Phase 3
380
Toyohashi, Aichi, Ehime, Gunma, Hyōgo, Kyoto, Numakunai, Okayama
2026-06-23
Recruiting
argenx
Phase 3
230
Okayama, Bunkyō-Ku, Ōta-ku, Iizuka, Kawasaki, Kitakyushu, Kyoto, Nagasaki
2026-06-10
Recruiting
GlaxoSmithKline
Phase 3
600
Aichi, Fukuoka, Hokkaido, Hyōgo, Kanagawa, Kyoto, Mie, Numakunai
2026-06-04
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Chiba, Fukuoka, Gunma, Kamakura-shi, Kyoto, Matsuyama, Okayama, Sapporo
2026-05-31
Recruiting
Kyowa Kirin Co., Ltd.
Phase 2
6
Chiba, Gifu, Hyōgo, Ibaraki, Kagoshima, Kanagawa, Kyoto, Miyagi
2026-04-23
Recruiting
Aesculap AG
Observational
178
Fukuoka, Okayama, Kyoto, Osaka-Fu, Osaka
2026-04-10
Recruiting
Astellas Pharma Inc
Phase 1/2
84
Sendai, Bunkyo-ku, Toyama, Kyoto, Tokushima
2026-04-03
Active, closed
Intuitive Surgical
Observational
625
Ichinomiya, Toyoake, Yokohama, Kyoto, Tsu, Ageo, Tokyo
2026-03-26
Active, closed
AbbVie
Phase 2
14
Nagoya, Yoshida-gun, Fukuoka, Maebashi, Hiroshima, Higashiibaraki-gun, Kyoto, Sakai-shi
2026-03-17
Recruiting
Astellas Pharma Global Development, Inc.
Phase 2
240
Gifu, Kobe, Tsukuba, Kawasaki, Bunkyo-ku, Koto-ku, Ube, Kyoto
2026-03-12
Active, closed
Ipsen
Phase 1
6
Kanagawa, Kobe, Kyoto, Osaka, Tokyo
2026-03-10
Recruiting
Regeneron Pharmaceuticals
Phase 3
1,120
Tōon, Akashi, Kita-gun, Isehara-Shi, Kyoto, Chuo, Ina-machi, Shinjuku
2026-03-09
Recruiting
AstraZeneca
Phase 3
508
Bunkyō City, Kashiwa, Kyoto, Nagoya, Shibuya-ku, Shinjuku-ku
2026-02-23
Recruiting
Eli Lilly and Company
Phase 3
900
Chūōku, Izumisano, Kawasaki, Kisarazu, Kure, Kyoto, Matsuyama, Osaka
2026-02-10
Recruiting
MSA-01 in Multiple System Atrophy
NCT07446894Multiple System Atrophy (MSA)
Tokyo University
Phase 3
140
Nagoya, Chiba, Fukuoka, Sapporo, Kagoshima, Kyoto, Okayama, Hasuda
2026-02-09
Recruiting
Genmab
Phase 2
240
Sagamihara, Yokohama, Kyoto, Nagoya, Saitama, Sakai, Chūō, Tokyo
2026-01-30
Recruiting
Sanofi
Phase 3
160
Kōriyama, Sapporo, Yahaba, Higashi-Matsuyama, Kodaira, Kyoto, Tokyo
2026-01-14
Recruiting
AbbVie
Phase 2/3
680
Nagoya, Matsuyama, Kurume-shi, Isehara, Kyoto
2026-01-08
Recruiting
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT07288359Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
DrugsLetrozole·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
205
Kyoto
2025-12-29
Recruiting
Pilot Study: Effects of CCP Intervention on NICU Environment and Preterm Infants Development
NCT07306000Preterm Infant Development, Preterm Infant Health
Turku University Hospital
Not applicable
100
Matsumoto, Kyoto
2025-12-22
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 4
20
Bunkyō City, Hirakata-shi, Iruma-Gun, Kyoto, Matsumoto-shi, Miyazaki, Nagoya, Nara
2025-12-19
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
DrugCetuximab
Revolution Medicines, Inc.
Phase 3
500
Yokohama, Chiba, Fukuoka, Kyoto, Tokyo
2025-12-15
By invitation
A Computer Game for Postpartum Mental Health After Emergency Cesarean Birth
NCT07290127Post-traumatic Stress Disorder (PTSD), Postpartum Mental Health
Kyoto University, Graduate School of Medicine
Not applicable
120
Kyoto
2025-12-13
Active, closed
Novartis Pharmaceuticals
Phase 2
234
Matsudo, Takamatsu, Miyhazaki, Suita, Shinjuku Ku, Kyoto
2025-12-02
Recruiting
AbbVie
Phase 2
100
Nagoya, Kashiwa-shi, Fukuoka, Sapporo, Kyoto, Sendai, Okayama, Chuo-Ku
2025-12-01
Recruiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Eli Lilly and Company
Phase 2
204
Himeji, Kōtoku, Kyoto, Nagaizumi-cho,Sunto-gun
2025-11-28
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed
AstraZeneca
Phase 1/2
152
Bunkyō City, Kashiwa, Kurume-shi, Kyoto, Niigata, Shinjuku-ku, Toyoake-shi
2025-11-24
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
14
Nagoya, Fukuoka, Hiroshima, Sapporo, Kyoto, Sendai, Niigata, Ōsaka-sayama
2025-11-19
Recruiting
AstraZeneca
Phase 3
400
Chūōku, Fukuoka, Hiroshima, Iwakuni-shi, Kashiwa, Kawasaki-shi, Kyoto, Matsuyama
2025-10-31
Recruiting
GlaxoSmithKline
Phase 3
1,200
Gifu, Kanagawa, Kyoto, Musashino, Yokohama
2025-10-24
Recruiting
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
Eli Lilly and Company
Phase 1
241
Chiba, Kyoto
2025-10-22
Recruiting
A Study of ZW251 in Participants With Advanced Solid Tumors
NCT07164313Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
Zymeworks BC Inc.
Phase 1
140
Kashiwa, Kyoto, Osaka, Tokyo
2025-10-21
Recruiting
Kazuya Hosokawa
Phase 4
36
Fukuoka, Kobe, Kyoto, Nagoya, Okayama, Sendai, Tokyo
2025-10-07
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 4
200
Bunkyō City, Kumamoto, Kurume-shi, Kyoto, Mitaka-shi, Nagoya, Nankoku-shi, Okayama
2025-10-01
By invitation
Impact of Comparing Treatment Status With Other CPAP Users
NCT07124975Sleep Apnea, Obstructive Sleep Apnea
Kimihiko Murase
Not applicable
186
Kyoto
2025-10-01
Recruiting
Daiichi Sankyo
Phase 2/3
630
Bunkyō City, Fukuoka, Hirosaki-shi, Kanazawa, Kawasaki, Kōtoku, Kumamoto, Kyoto
2025-09-26
Recruiting
Sanofi
Phase 4
218
Ube, Kyoto, Osaka
2025-09-22
Active, closed
Hoffmann-La Roche
Phase 3
1,101
Kyoto, Meguro-Ku, Mie, Tokyo, Yamagata
2025-09-17
Not yet open
LTFU for All Cell and Gene Therapy Studies
NCT06194461Hepatocellular Carcinoma, Prostate Cancer
DrugsAZD0754·AZD5851
AstraZeneca
Observational
64
Kashiwa, Kyoto, Osakasayama-shi
2025-09-17
Recruiting
AbbVie
Observational
700
Maebashi, Asahikawa-shi, Sapporo, Kagoshima, Isehara, Yokohama, Kyoto, Kurashiki
2025-09-09
Recruiting
CSL Behring
Phase 2
180
Chikushino-shi, Fukuoka, Ibaraki, Iizuka-shi, Kyoto, Mie, Osaka, Shimonoseki-shi
2025-09-03
Recruiting
Pfizer
Phase 3
6,000
Kurume, Sendai, Beppu-shi, Habikino, Izumisano, Kofu, Fukui, Kyoto
2025-08-25
Recruiting
GlaxoSmithKline
Phase 3
420
Fukuoka, Hokkaido, Ishikawa, Kagoshima, Kanagawa, Kochi, Kyoto, Mie
2025-08-11
Recruiting
AstraZeneca
Phase 2
278
Bunkyō City, Fukuyama-shi, Kobe, Kurume-shi, Kyoto, Osaka, Sakaishi, Shinjuku-ku
2025-08-07
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
Chiba, Kyoto, Osaka
2025-08-06
Recruiting
AstraZeneca
Phase 3
700
Bunkyō City, Fukuoka, Kamakura-shi, Kawagoe-shi, Kawasaki-shi, Kisarazu-shi, Kumamoto, Kyoto
2025-08-06
Recruiting
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis
DrugsCisplatin·Carboplatin·Pembrolizumab
Eli Lilly and Company
Phase 1
240
Kyoto, Tokyo
2025-07-28
Recruiting
Sanofi
Phase 2
10
Sapporo, Kobe, Yokohama, Iruma, Chūō, Fukuoka, Kyoto, Nagasaki
2025-07-25
Recruiting
AbbVie
Phase 1/2
325
Nagoya, Kyoto, Suita-shi, Shibuya-ku, Tokyo
2025-07-23
Active, closed
Astellas Pharma Inc
Phase 4
17
Nagoya, Fukushima, Kita-gun, Yokohama, Kyoto, Nagasaki, Ginowan-shi, Hirakata-shi
2025-07-08
Recruiting
Hoffmann-La Roche
Phase 3
80,000
Aichi, Hiroshima, Hyōgo, Kagawa, Kanagawa, Kochi, Kyoto, Meguro-Ku
2025-07-02
Recruiting
AbbVie
Phase 1/2
602
Nagoya, Kyoto, Suita-shi, Shibuya-ku
2025-06-30
Recruiting
Calico Life Sciences LLC
Phase 2
240
Chiba, Sapporo, Kyoto, Bunkyō-Ku
2025-06-09
Active, closed
Merck Sharp & Dohme LLC
Phase 2
149
Nagoya, Sapporo, Ginowan, tabashi City, Fukuoka, Kyoto
2025-06-09
Active, closed
Stoke Therapeutics, Inc
Phase 3
170
Fukuoka, Hokkaido, Kyoto, Nagoya, Niigata, Okayama, Osaka, Shimotsuke
2025-06-04
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 3
450
Kyoto, Suita-shi
2025-05-19
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Nagoya, Matsudo, Kawasaki, Yokohama, Habikino, Shinagawa Ku, Fukuoka, Kyoto
2025-05-16
Recruiting
Joseph Broderick, MD
Phase 3
350
Suita, Fukuoka, Gifu, Kagoshima, Kobe, Kyoto, Niigata, Osaka
2025-05-06
Recruiting
AstraZeneca
Phase 1
72
Bunkyō City, Kita-gun, Kitakyushu-shi, Kyoto, Nagasaki
2025-05-01
Active, closed
Novartis Pharmaceuticals
Phase 1/2
15
Chiba, Kyoto
2025-04-22
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
35
Nagoya, Kashiwa, Kurume, Nishinomiya, Sagamihara, Yokohama, Nankoku, Kyoto
2025-04-21
Recruiting
PharmaBio Corporation
Not applicable
6
Kyoto
2025-04-15
Recruiting
AbbVie
Phase 1/2
252
Nagoya, Hirosaki, Yokohama, Kyoto, Niigata, Takatsuki, Chuo-Ku, Koto-ku
2025-03-06
Recruiting
Summit Therapeutics
Phase 3
780
Nagoya, Kurume, Asahikawa, Nishinomiya, Kanazawa, Tokyo, Kumamoto, Kyoto
2025-02-27
Recruiting
NovoCure GmbH
Phase 3
741
Toyoake-shi, Isehara, Fukuoka, Hokkaido, Ishikawa, Kumamoto, Kyoto, Mitaka
2025-02-03
Active, closed
Institut de Recherches Internationales Servier
Phase 1/2
51
Kumamoto, Kyoto, Nagoya, Tokyo
2025-01-22
Recruiting
Kyoto University
Phase 4
1,200
Kyoto
2025-01-20
Recruiting
Rakuten Medical, Inc.
Phase 3
412
Aichi, Hiroshima, Kyoto, Tokyo, Yonago
2024-12-24
Active, closed
AbbVie
Phase 2
83
Sapporo, Kyoto, Tachikawa-shi
2024-12-19
Active, closed
Institut de Recherches Internationales Servier
Phase 1/2
55
Kashiwa, Chūōku, Kyoto, Yokohama
2024-12-16
Recruiting
National Cancer Center, Japan
Phase 2
38
Kashiwa, Kyoto, Miyazaki, Nagoya, Tokyo
2024-12-01
Recruiting
Eli Lilly and Company
Phase 3
125
Iruma-Gun, Isesaki-shi, Kyoto, Meguro-Ku, Moriyama, Nara, Osaka, Saga
2024-11-18
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Sapporo, Sendai, Suita, Bunkyo-ku, Fukuoka, Ishikawa, Kyoto
2024-10-29
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Drugs5Fluorouracil·Leucovorin·Irinotecan·Cetuximab
Eli Lilly and Company
Phase 1
750
Chiba, Kyoto, Shizuoka, Tokyo
2024-10-21
Active, closed
Ipsen
Phase 2
670
Fukuoka, Hiroshima, Hyōgo, Kagoshima, Kyoto, Miyagi, Osaka, Shizuoka
2024-10-10
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
2,150
Ōgaki, Maebashi, Fukui-shi, Yokohama, Kyoto, Suita-shi, Bunkyō-Ku, Minato-Ku
2024-10-04
By invitation
Sanofi
Phase 2
900
Sakaidechō, Chūō, Ube, Fukushima, Kyoto, Miyazaki
2024-09-30
Active, closed
ModernaTX, Inc.
Phase 3
37,864
Nagoya, Hiroshima, Sapporo, Fukuoka, Kawasaki-shi, Kyoto, Minoh, Kawagoe-shi
2024-09-24
Active, closed
argenx
Phase 3
141
Chūōku, Fukuoka, Hanamaki-shi, Hiroshima, Kawagoe, Kyoto, Narita, Sapporo
2024-09-18
Recruiting
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
NCT06351592Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene
Regeneron Pharmaceuticals
Phase 1/2
54
Sapporo, Tokushima, Ōta-ku, Kyoto
2024-08-28
Active, closed
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
Alterome Therapeutics, Inc.
Phase 1
110
Kyoto, Tokyo
2024-08-22
Recruiting
Colorado Prevention Center
Phase 3
2,600
Sapporo, Isehara, Sagamihara, Kyoto, Sendai, Osaka, Suita, Ōta-ku
2024-08-20
Recruiting
Sumitomo Pharma America, Inc.
Phase 1/2
120
Kashiwa-shi, Kyoto
2024-08-14
Recruiting
Jazz Pharmaceuticals
Phase 3
550
Chiba, Chūōku, Fukuoka, Fukushima, Hidaka-shi, Isesaki-shi, Kagoshima, Kyoto
2024-08-13
Active, closed
Belite Bio, Inc
Phase 2/3
60
Kobe, Kyoto, Tokyo
2024-07-31
Recruiting
Boehringer Ingelheim
Phase 1/2
768
Aichi, Nagoya, Isehara, Kagoshima, Kanagawa, Yokohama, Kashiwa-shi, Kyoto, Osaka, Tokyo, Koto-ku
2024-06-28
Active, closed
AbbVie
Phase 3
1,400
Nagoya, Toyoake, Obihiro-Shi, Shiwa-gun, Kyoto, Niigata, Ginowan-shi, Osaka
2024-06-27
Active, closed
AbbVie
Phase 3
184
Ichinomiya, Marugame, Kyoto, Kurashiki, Mibu, Suginami-Ku, Tachikawa-shi, Kofu
2024-06-14
Active, closed
GlaxoSmithKline
Phase 3
88
Aichi, Ehime, Fukuoka, Hokkaido, Hyōgo, Kyoto, Mie, Miyagi
2024-06-10
Active, closed
Osamu Ukimura
Not applicable
65
Kyoto
2024-05-01
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Chiba, Morioka, Sagamihara-shi, Kyoto, Sendai, Moriguchi-shi, Osaka, Kawagoe-shi
2024-04-16
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
230
Nagoya, Nishinomiya, Shibuya-ku, Chiba, Kyoto
2024-03-21
Active, closed
Kite, A Gilead Company
Phase 2
25
Chiba, Fukuoka, Hokkaido, Kyoto, Miyagi, Okayama, Tokyo
2024-03-18
Active, closed
AbbVie
Phase 1
152
Kashiwa-shi, Kyoto, Chuo-ku
2024-03-08
Active, closed
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
490
Chūōku, Kashiwa, Kōtō City, Kyoto
2024-03-05
Recruiting
AstraZeneca
Phase 3
5,250
Chūōku, Fujieda-shi, Fukuoka, Kitakyushu, Kobe, Kure-shi, Kyoto, Minoh
2024-02-21
Recruiting
Eisai Co., Ltd.
Observational
5,000
Hiroshima, Kyoto, Tokyo
2024-02-14
Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase
DrugsBosutinib·Olverembatinib
Ascentage Pharma Group Inc.
Phase 3
333
Ehime, Kyoto, Okayama, Osaka, Sapporo, Tochigi, Tokyo, Yamagata
2024-02-05
Active, closed
Incyte Corporation
Phase 3
617
Ginowan-shi, Itabashi-ku, Kurume-shi, Kyoto, Niigata, Sapporo, Sendai, Shinjuku-ku
2024-01-30
Active, closed
Janssen Research & Development, LLC
Phase 3
838
Bunkyō City, Fukuoka, Hamamatsu, Kanazawa, Kyoto, Nagasaki, Narita, Niigata
2024-01-22
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,181
Bunkyō City, Kumamoto, Kurume-shi, Kyoto, Matsumoto-shi, Sapporo, Shinjuku-ku, Suita-shi
2024-01-11
By invitation
5-SENSE Score Validation Study
NCT06138808Epilepsy Intractable
Duke University
Observational
400
Kyoto
2024-01-09
Recruiting
A Global Study of the PETAL Consortium
NCT06067347T-Cell and NK-Cell Neoplasm
Massachusetts General Hospital
Observational
1,200
Kyoto
2024-01-05
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Bunkyō City, Chiba, Chūōku, Fukuoka, Kashiwa, Kyoto, Okayama, Osaka
2023-12-29
Active, closed
Study of Tamibarotene in Patients With ADPKD
NCT06289998Autosomal Dominant Polycystic Kidney Disease (ADPKD)
DrugTamibarotene
Rege Nephro Co., Ltd.
Phase 2
70
Kurume, Sapporo, Kamakura, Kawasaki, Kyoto, Bunkyo-ku, Minato-ku, Shinjukuku
2023-12-22
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Nagoya, Kashiwa-shi, Kurume, Kanazawa, Yokohama, Kyoto, Sendai, Ōsaka-sayama
2023-12-20
Active, closed
AbbVie
Observational
250
Matsuyama, Asahikawa, Hakodate-shi, Ryūgasaki, Tsukuba, Kagoshima, Kyoto, Sendai
2023-11-30
Active, closed
Incyte Corporation
Phase 3
467
Hamamatsu, Kawasaki, Kobe, Kyoto, Minamikoshigaya, Nagasaki, Nagoya, Nankoku
2023-11-29
Active, closed
AbbVie
Phase 2
280
Nagoya, Kashiwa-shi, Kyoto, Sunto-gun, Chuo-ku
2023-11-12
Recruiting
AbbVie
Phase 1
325
Nagoya, Kashiwa-shi, Kyoto, Sunto-gun, Chuo-Ku, Koto-ku
2023-11-09
Recruiting
NRG Oncology
Phase 3
3,960
Tōon, Sapporo, Akashi, Gunma, Koto-ku, Hiroshima, Kyoto, Matsuyama
2023-10-18
Recruiting
Pfizer
Phase 4
80
Shibuya-ku, Kyoto
2023-10-03
Recruiting
Kyoto University Hospital
Phase 2
30
Kobe, Tsukuba, Kyoto, Osaka
2023-10-01
Active, closed
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
NCT06547528Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DrugONO-4685
Ono Pharmaceutical Co., Ltd.
Phase 1
108
Nagoya, Akita, Kashiwa-shi, Fukuoka, Sapporo, Isehara-shi, Kumamoto, Kyoto
2023-10-01
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 2
92
Toyoake, Kyoto, Sendai, Toyonaka, Fuchū
2023-09-22
Active, closed
Hoffmann-La Roche
Phase 3
1,130
Aichi, Chiba, Fukuoka, Gifu, Hokkaido, Hyōgo, Kanagawa, Kyoto
2023-09-18
Recruiting
Hoffmann-La Roche
Phase 3
230
Aichi, Chiba, Hiroshima, Kagoshima, Kanagawa, Kyoto, Matsuyama, Saitama
2023-09-08
Active, closed
Cytokinetics
Phase 3
500
Fukuoka, Hyōgo, Ibaraki, Kanagawa, Kochi, Kyoto, Mie, Miyagi
2023-08-31
Active, closed
Pharming Technologies B.V.
Phase 3
16
Kyoto, Tokyo
2023-08-30
Active, closed
AstraZeneca
Phase 3
142
Chūōku, Kanazawa, Kashiwa, Kyoto, Osaka, Sendai, Ube, Wakayama
2023-08-16
Recruiting
GlaxoSmithKline
Phase 3
892
Aichi, Chiba, Fukuoka, Hokkaido, Hyōgo, Ibaraki, Kanagawa, Kyoto
2023-08-01
By invitation
A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
NCT05777993Pyruvate Kinase Deficiency, Anemia, Hemolytic, Sickle Cell Disease, Thalassemia
DrugMitapivat
Agios Pharmaceuticals, Inc.
Phase 4
59
Sendai, Kyoto, Ōta-ku
2023-07-06
Active, closed
Effect of Respiratory Virus Infection on EmeRgencY Admission Study (EVERY Study)
NCT05913700Respiratory Syncytial Virus (RSV), Respiratory Viral Infection, Acute Disease
Institute for Clinical Effectiveness, Japan
Observational
3,067
Kyoto, Nara, Izumo
2023-07-01
Active, closed
AbbVie
Phase 3
1,328
Fukuoka, Nishinomiya-shi, Tsukuba, Kyoto, Sendai, Ginowan-shi, Sakai-shi, Ōtsu
2023-06-21
Active, closed
AbbVie
Phase 1
135
Kashiwa-shi, Kyoto, Chuo-ku, Koto-ku
2023-06-09
By invitation
AbbVie
Phase 3
650
Kobe, Nishinomiya-shi, Kochi, Sendai, Osaka, Shinjuku-ku, Kyoto
2023-06-05
Recruiting
AbbVie
Phase 3
450
Kobe, Nishinomiya, Kochi, Sendai, Osaka, Shinjuku-ku, Kyoto
2023-05-01
Recruiting
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT05786924Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
DrugsPanitumumab·Folfox·Cetuximab·Nab-paclitaxel
Institut de Recherches Internationales Servier
Phase 1/2
554
Kanagawa, Kyoto, Tokyo
2023-04-18
Recruiting
Eli Lilly and Company
Phase 1/2
880
Fukuoka, Hirakata, Kōtō City, Kyoto
2023-04-17
Active, closed
Bayer
Phase 3
985
Sapporo, Kanazawa, Yokohama, Suita, Bunkyo-ku, Kyoto
2023-04-03
Recruiting
National Cancer Center, Japan
Phase 2
32
Kashiwa, Sapporo, Kyoto, Sendai, Chuo-ku, Fukuoka
2023-03-29
By invitation
Eli Lilly and Company
Phase 3
333
Toyoake, Fukuyama, Hiroshima, Asahikawa, Sagamihara, Kyoto, Ina, Okayama
2023-03-09
Active, closed
Kite, A Gilead Company
Phase 3
300
Kyoto, Miyagi, Osaka, Tokyo
2023-02-10
Active, closed
Pharming Technologies B.V.
Phase 3
15
Kyoto, Tokyo
2023-02-01
Recruiting
Jazz Pharmaceuticals
Phase 3
510
Chūō, Fukuoka, Kyoto, Osaka, Sapporo, Tokyo
2023-01-23
Active, closed
Sanofi
Phase 2
68
Nagoya, Kashiwa, Kitakyushu, Sapporo, Kamakura, Shimizu, Bunkyo, Kyoto
2023-01-12
Recruiting
Princess Maxima Center for Pediatric Oncology
Phase 3
160
Chiba, Ehime, Hiroshima, Hokkaido, Hyōgo, Kagoshima, Kanagawa, Kyoto
2022-12-15
Active, closed
AbbVie
Phase 1
288
Kashiwa-shi, Matsuyama, Sapporo, Kyoto, Sunto-gun, Chuo-ku, Koto-ku, Wakayama
2022-12-05
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
80
Bunkyō City, Kyoto, Osaka, Shibuya-ku, Tsukuba
2022-10-28
Active, closed
NRG Oncology
Phase 3
237
Sapporo, Gunma, Kyoto, Showa-Ku Nagoya, Tokyo
2022-10-24
Active, closed
Eli Lilly and Company
Phase 3
377
Asahikawa, Fukuyama, Habikino, Hiroshima, Ina, Kumagaya, Kyoto, Okayama
2022-10-18
Active, closed
Eli Lilly and Company
Phase 3
15,374
Chūōku, Fukuoka, Izumisano, Kyoto, Minatoku, Onga-gun, Osaka, Uji
2022-10-11
Active, closed
Genmab
Phase 1
17
Nagoya, Kyoto, Osaka, Chuo-ku, Setagaya-ku
2022-10-04
Active, closed
Kite, A Gilead Company
Phase 3
231
Hyōgo, Kyoto, Miyagi, Okayama, Osaka
2022-09-22
Active, closed
Novo Nordisk A/S
Phase 3
412
Fukuoka-shi, Fukuoka, Kobe-shi, Hyogo, Kyoto, Nara-shi, Nara, Niigata-shi, Niigata, Okayama-shi, Okayama, Osaka, Saitama-shi, Saitama
2022-08-10
Active, closed
Novartis Pharmaceuticals
Phase 3
610
Miyhazaki, Urasoe, Izumisano, Kyoto
2022-07-08
Active, closed
Sanofi
Phase 3
531
Nagoya, Kamogawa, Higashiibaraki, Yahaba, Kamakura, Okayama, Kyoto, Osaka
2022-06-23
Active, closed
Genmab
Phase 2
264
Sapporo, Kyoto, Chuo-ku
2022-06-14
Recruiting
Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization
NCT05347069Stable Angina Pectoris, Coronary Artery Disease, Ischemic Heart Disease
DrugsNo aspirin·Aspirin
Takeshi Morimoto
Phase 4
2,890
Kyoto
2022-06-14
Recruiting
Innovacell GmbH
Phase 3
290
Sapporo, Chiba, Fukuoka, Hiroshima, Hyōgo, Kanagawa, Kumamoto, Kyoto
2022-05-11
Active, closed
Eli Lilly and Company
Phase 1
260
Chūōku, Kōtō City, Kyoto, Nagoya
2022-05-11
Active, closed
Pfizer
Phase 3
854
Nagoya, Maebashi, Kobe, Yahaba-cho, Kyoto, Sendai, Hamamatsu, Sunto-gun
2022-03-25
Active, closed
AstraZeneca
Phase 3
390
Chiba, Fukuoka, Hiroshima, Kashiwa, Kōtoku, Kyoto, Niigata, Osaka
2022-02-21
By invitation
UCB Biopharma SRL
Phase 3
300
Fukuoka, Hachioji-shi, Hiroshima, Hōfu, Itami, Kodaira, Koshi-shi, Kyoto
2022-02-03
Active, closed
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05002127Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
DrugsEvorpacept·Ramucirumab·Herceptin·Taxol
ALX Oncology Inc.
Phase 2/3
127
Chiba, Fukuoka, Gifu, Kumamoto, Kyoto, Nagasaki, Osaka, Ōita
2022-01-15
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
DrugsEylea·Aflibercept
AbbVie
Phase 3
735
Nagoya, Fukushima, Kobe, Nishinomiya-shi, Kagoshima, Kyoto, Miyazaki, Ōtsu
2022-01-13
Active, closed
AbbVie
Phase 2
210
Nagoya, Fukuoka, Kyoto, Nakagami-gun, Osakasayama-shi
2021-12-28
By invitation
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
NCT05041309Solid and Hematological Malignancies, Autoimmune Diseases
DrugsKITE-197·SPRX002·KITE-753·Tecartus
Kite, A Gilead Company
Observational
1,500
Fukuoka, Kyoto, Okayama, Sapporo Hokkaido, Sendai, Tokyo
2021-12-15
Active, closed
Joseph Broderick, MD
Phase 3
860
Suita, Fukuoka, Gifu, Kagoshima, Kobe, Kyoto, Morioka, Niigata
2021-12-03
Active, closed
Hoffmann-La Roche
Phase 3
478
Aichi, Chiba, Kyoto, Mie, Miyagi, Okayama, Tokyo
2021-10-27
Active, closed
AbbVie
Phase 1
520
Nagoya, Kashiwa-shi, Yokohama, Kyoto, Niigata, Chuo-ku, Koto-ku, Wakayama
2021-10-13
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Kasugai, Toyoake, Toyota, Sapporo, Kawasaki, Yokohama, Kyoto, Sendai
2021-09-20
Active, closed
Loxo Oncology, Inc.
Phase 3
600
Bunkyō City, Chiba-Ken, Chūō, Chūōku, Fukui, Kōtō City, Kyoto, Nankoku
2021-09-20
Active, closed
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
NCT05023551High Grade Glioma, Glioblastoma Multiforme
Sumitomo Pharma America, Inc.
Early Phase 1
39
Sapporo, Kyoto, Chuo Ku
2021-09-08
Active, closed
Janssen Research & Development, LLC
Phase 3
743
Bunkyō City, Fukuoka, Hyôgo, Kanazawa, Kyoto, Nagoya, Okayama, Sapporo
2021-08-19
Recruiting
Merck Sharp & Dohme LLC
Phase 2
355
Sapporo, Yokohama, Nankoku, Chuo-ku, Kyoto, Tokyo
2021-08-12
Active, closed
Regeneron Pharmaceuticals
Observational
717
Yoshida-gun, Fujisawa, Nagaoka, Habikino, Meguro-Ku, Shinagawa-Ku, Kyoto
2021-08-12
Active, closed
Novartis Pharmaceuticals
Phase 3
208
Nagoya, Isehara, Suwa, Suita, Shinjuku Ku, Fukushima, Ishikawa, Kyoto
2021-07-27
Recruiting
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
NCT04613921Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications
European Foundation for Study of Chronic Liver Failure
Observational
3,000
Fukuoka, Hiroshima, Kyoto, Nagasaki, Tokyo
2021-07-08
Recruiting
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 3
434
Hokkaido, Kobe, Kumamoto, Kyoto, Nagasaki, Osaka, Saitama, Toyoake
2021-07-06
Recruiting
NRG Oncology
Phase 3
1,670
Tōon, Sapporo, Akashi, Gunma, Koto-ku, Hiroshima, Kyoto, Matsuyama
2021-06-23
Active, closed
Daiichi Sankyo
Phase 2
155
Nagoya, Kashiwa, Sapporo, Chuo Ku, Fukuoka, Kagoshima, Kyoto, Nagasaki
2021-06-03
Active, closed
AstraZeneca
Phase 3
893
Chiba, Chūōku, Hidaka-shi, Hiroshima, Isehara-shi, Kagoshima, Kōtoku, Kyoto
2021-05-10
Active, closed
Hoffmann-La Roche
Phase 3
761
Aichi, Chiba, Ehime, Hiroshima, Hokkaido, Ibaraki, Kanagawa, Kyoto
2021-05-03
Recruiting
Boston Scientific Corporation
Observational
5,000
Sapporo, Kyoto, Miyazaki, Aichi, Chiba, Osaka
2021-03-29
Active, closed
Hoffmann-La Roche
Phase 1/2
241
Kyoto, Tokyo
2021-03-15
Recruiting
UCB Biopharma SRL
Phase 3
70
Bunkyō City, Chūō, Gifu, Hiroshima, Kodaira-shi, Kōshi, Kyoto, Nagoya
2021-03-11
Active, closed
GOREISAN for Heart Failure (GOREISAN-HF) Trial
NCT04691700Heart Failure, Edema, Traditional Japanese Medicine, Kampo Medicine
Takeshi Morimoto
Phase 4
1,179
Kyoto
2021-01-19
Active, closed
Genmab
Phase 3
483
Fukuoka, Fukushima, Fukuyama, Hokkaido, Kashiwa, Kyoto, Matsuyama, Mie
2021-01-13
Active, closed
AstraZeneca
Phase 3
358
Akashi-shi, Bunkyō City, Chiba, Hiroshima, Kashiwa, Kōtoku, Kyoto, Niigata
2020-12-16
Active, closed
GlaxoSmithKline
Phase 2/3
758
Kyoto, Miyagi, Osaka, Yamaguchi
2020-12-08
Active, closed
Amgen
Phase 3
135
Fukuoka, Hokkaido, Hyōgo, Ishikawa, Kyoto, Niigata, Osaka, Tokyo
2020-12-04
Active, closed
Eli Lilly and Company
Phase 3
312
Kagoshima, Kobe, Kochi, Kyoto, Nishinomiya, Osaka, Shinjuku-ku, Tokyo
2020-11-25
Recruiting
Taiho Pharmaceutical Co., Ltd.
Phase 1
59
Bunkyō City, Fukushima, Iruma, Kyoto, Nagasaki, Osaka, Sakai, Shinagawa-Ku
2020-10-30
Active, closed
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT04452591Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
DrugCretostimogene Grenadenorepvec
CG Oncology, Inc.
Phase 3
190
Kashiwa-shi, Tōon, Sapporo, Kandori, Marugame, Kawasaki, Yokohama, Kyoto
2020-10-27
Recruiting
Predicting BCG Response
NCT04564781Bladder Cancer
Cedars-Sinai Medical Center
Observational
400
Kyoto
2020-09-18
Active, closed
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
NCT04542824Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma
DrugsRituximab and lenalidomide·Gemcitabine and oxaliplatin·Epcoritamab·Lenvatinib
Genmab
Phase 1/2
78
Sendai, Aichi, Chiba, Ehime, Fukuoka, Fukushima, Kagoshima, Kyoto
2020-08-20
Active, closed
Incyte Corporation
Phase 2
112
Bunkyō City, Chūō, Hirakata, Isehara, Kobe, Kyoto, Matsumoto-shi, Miyagi
2020-08-03
Active, closed
Eisai Inc.
Phase 3
1,400
Obu-shi, Fukuoka, Kobe, Kamakura-shi, Kyoto, Sendai, Osaka, Suita-shi
2020-07-14
Active, closed
Daiichi Sankyo Co., Ltd.
Phase 2
25
Nagoya, Sagamihara, Sendai, Hidaka, Hiroshima, Kumamoto, Kyoto, Osaka
2020-07-08
Active, closed
Janssen Research & Development, LLC
Phase 3
419
Fukuoka, Kanazawa, Kyoto, Nagoya, Okayama, Sapporo, Sendai, Shibuya City
2020-06-12
Active, closed
AstraZeneca
Phase 3
805
Chūōku, Kashiwa-shi, Kōtoku, Kurume-shi, Kyoto, Matsuyama, Minatoku, Nagoya
2020-05-05
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
886
Bunkyō City, Chiba, Fukuoka, Hirosaki, Kawasaki-shi, Kōtoku, Kyoto, Niigata
2020-03-30
Recruiting
Eisai Co., Ltd.
Phase 1
18
Hakata, Kurume, Yuhu, Bukyo-ku, Mintato-ku, Shinjuku-ku, Kofu, Kyoto
2020-02-27
Active, closed
Institut de Recherches Internationales Servier
Phase 3
331
Nagoya, Toyoake, Minami-Ku, Bunkyō-Ku, Chuo Ku, Kumamoto, Kyoto, Okayama
2020-01-05
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Nagoya, Chiba, Kashiwa-shi, Matsuyama, Fukuoka, Kobe, Isehara-Shi, Kyoto
2019-11-13
Active, closed
BeOne Medicines
Phase 3
510
Nagoya, Toyohashi, Chiba, Kurume, Hiroshima, Yokohama, Kumamoto, Kyoto
2019-08-20
Active, closed
Novo Nordisk A/S
Phase 2
62
Fukuoka, Fukuoka-shi, Fukuoka, Fukuyama-shi, Hiroshima, Kobe-shi, Hyogo, Kyoto, Nara-shi, Nara, Niigata-shi, Niigata, Osaka
2019-07-04
Active, closed
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
NCT03899792Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
DrugSelpercatinib
Eli Lilly and Company
Phase 1/2
36
Sapporo, Chuo-ku, Hiroshima, Kyoto
2019-06-13
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
387
Nagoya, Kashiwa-shi, Maebashi, Kasama-shi, Kyoto, Hidaka, Tokushima, Shibuya-ku
2019-01-23
Active, closed
AstraZeneca
Phase 3
1,407
Fukuoka, Kashiwa-shi, Kobe, Kōtoku, Kurume-shi, Kyoto, Minatoku, Nagoya
2019-01-04
Active, closed
Merck Sharp & Dohme LLC
Phase 2
329
Nagoya, Kashiwa, Kyoto, Suita, Tokyo
2018-12-12
Active, closed
AstraZeneca
Phase 3
895
Bunkyō City, Hirakata-shi, Kanazawa, Kashihara-shi, Kawagoe-shi, Kita-gun, Kyoto, Maebashi
2018-10-31
Active, closed
AbbVie
Phase 3
1,533
Nagoya, Fukuoka, Hiroshima, Sapporo, Amagasaki-shi, Sagamihara-shi, Yokohama, Kyoto
2018-08-09
Active, closed
Eli Lilly and Company
Phase 3
533
Kobe, Kochi, Kyoto, Nishinomiya, Osaka, Sendai, Shinjuku-ku, Tokyo
2018-03-14
Active, closed
Kyoto Prefectural University of Medicine
Phase 3
160
Kyoto
2017-09-25
Active, closed
Hoffmann-La Roche
Phase 2/3
1,000
Bunkyō City, Fukuoka, Hiroshima, Ishikawa, Kanagawa, Kyoto, Matsuyama, Miyagi
2017-09-22
Active, closed
Acerta Pharma BV
Phase 3
635
Fukuoka, Kobe, Kyoto, Matsuyama, Nagoya, Osaka, Sapporo, Sendai
2017-04-05
Active, closed
AbbVie
Phase 3
443
Nagoya, Yoshida-gun, Fukuoka, Maebashi, Higashi, Hitachi-shi, Kyoto, Sendai
2017-02-02
Recruiting
A Randomized Multicenter Study for Isolated Skin Vasculitis
NCT02939573Primary Cutaneous Vasculitis, Cutaneous Polyarteritis Nodosa, IgA Vasculitis, Henoch-Schönlein Purpura
DrugsDapsone·Azathioprine·Colchicine
University of Pennsylvania
Phase 2
90
Kyoto
2017-01-01
Recruiting
Cedars-Sinai Medical Center
Observational
300
Kyoto
2016-12-30
Active, closed
Celgene
Phase 1/2
466
Matsuyama, Aomori, Hiroshima, Isehara City, Kanagawa, Kamogawa, Kyoto, Nagasaki, Nagoya
2016-10-14
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Sapporo, Sendai, Chuo Ku, Fukuoka, Kyoto
2015-11-02
Active, closed
Alliance Foundation Trials, LLC.
Phase 3
5,796
Nagoya, Sapporo, Chiba, Kyoto, Osaka
2015-08
Active, closed
ETOP IBCSG Partners Foundation
Not applicable
518
Amagasaki, Hamamatsu, Fukuoka, Kagoshima, Kawasaki, Kyoto, Matsuyama, Minato-ku, Tokyo
2014-12-04
Recruiting
Pompe Disease Registry Protocol
NCT00231400Glycogen Storage Disease Type II, Pompe Disease
Genzyme, a Sanofi Company
Observational
2,000
Ginowan, Kyoto
2004-09-15
Recruiting
Manuel Monreal
Observational
120,000
Kitakyushu, Maebashi, Amagasaki, Kumamoto, Kyoto, Tsu, Nagasaki, Osaka
2001-03
Rows per page Showing 1–231 of 231
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/kyoto

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 231 of those studies with a site in Kyoto.

How many clinical trials are recruiting in Kyoto?

108 of the 231 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 5 have not yet opened recruitment, 109 are active but closed to new participants, and 9 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Kyoto), 231 studies
PhaseStudiesRecruitingShare
Phase 31064445.9%
Phase 2381716.5%
Phase 122109.5%
Phase 1/222159.5%
Observational19118.2%
Phase 41074.3%
Not applicable723%
Phase 2/3622.6%
Early Phase 1100.4%

Most active sponsors

Lead sponsors with the most studies (Kyoto)
Lead sponsorStudiesRecruiting
AbbVie248
AstraZeneca2113
Eli Lilly and Company178
Novartis Pharmaceuticals105
Hoffmann-La Roche93
GlaxoSmithKline74
Sanofi73
Alexion Pharmaceuticals, Inc.63
Regeneron Pharmaceuticals64
Genmab51
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.